Simple Summary Pancreatic neuroendocrine tumors (pNETs) are rare, indolent cancers
whose causation is only partly understood. An increasing number of studies have uncovered …

Neuroendocrine tumors (NETs) include a heterogeneous group of malignancies arising in
the diffuse neuroendocrine system and characterized by indolent growth. Complex …

Gastroenteropancreatic neuroendocrine neoplasms are heterogeneous in their clinical
behavior and require therapies specially tailored according to staging, grading, origin and …

Alkylating agents, such as streptozocin and dacarbazine, have been reported as active in
neuroendocrine neoplasms (NENs). Temozolomide (TMZ) is an oral, potentially less toxic …

In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has
changed dramatically following the approval of several novel targeted treatments. The …

Gut microbiota is represented by different microorganisms that colonize the intestinal tract,
mostly the large intestine, such as bacteria, fungi, archaea and viruses. The gut microbial …

Pancreatic neuroendocrine tumors (PanNETs) are a rare tumor entity with largely
unpredictable progression and increasing incidence in developed countries. Molecular …

Significant improvements have taken place in our understanding of classification
neuroendocrine neoplasms of the pancreas in the past decade. These are now regarded in …

Molecular targeted therapy of advanced neuroendocrine tumours (NETs) of the
gastroenteropancreatic (GEP) system currently encompasses approved therapy with the …

Abstract 177Lu‑DOTATATE was recently approved for the treatment of somatostatin receptor
(SSTR)‑positive neuroendocrine tumors (NETs). However, despite impressive response …